CA2160135A1 - Methode pour depister les agonistes de recepteurs - Google Patents

Methode pour depister les agonistes de recepteurs

Info

Publication number
CA2160135A1
CA2160135A1 CA002160135A CA2160135A CA2160135A1 CA 2160135 A1 CA2160135 A1 CA 2160135A1 CA 002160135 A CA002160135 A CA 002160135A CA 2160135 A CA2160135 A CA 2160135A CA 2160135 A1 CA2160135 A1 CA 2160135A1
Authority
CA
Canada
Prior art keywords
receptor
promoter
cell
region
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002160135A
Other languages
English (en)
Inventor
Donald P. Mcdonnell
Maty Tzukerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2160135A1 publication Critical patent/CA2160135A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002160135A 1993-04-07 1994-04-06 Methode pour depister les agonistes de recepteurs Abandoned CA2160135A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4580793A 1993-04-07 1993-04-07
US17975094A 1994-01-10 1994-01-10
US08/045,807 1994-01-10
US08/179,750 1994-01-10

Publications (1)

Publication Number Publication Date
CA2160135A1 true CA2160135A1 (fr) 1994-10-13

Family

ID=26723218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002160135A Abandoned CA2160135A1 (fr) 1993-04-07 1994-04-06 Methode pour depister les agonistes de recepteurs

Country Status (6)

Country Link
EP (1) EP0694078A4 (fr)
JP (1) JPH08512197A (fr)
AU (1) AU6556194A (fr)
BR (1) BR9406616A (fr)
CA (1) CA2160135A1 (fr)
WO (1) WO1994023068A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688112B2 (en) * 1994-08-22 1998-03-05 Eli Lilly And Company Methods of inhibiting endometrial cancer
AU6263996A (en) * 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
US6692928B1 (en) 1996-07-19 2004-02-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular agents
US5728534A (en) 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents
AU4676999A (en) 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
BRPI0107715B8 (pt) 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1388352A1 (fr) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
EP1656142A4 (fr) 2003-08-22 2011-06-22 Ligand Pharm Inc Derives de 6-cycloamino-2-quinolinone utilises comme composes modulateurs des recepteurs d'androgenes
CN102908351B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
RS53176B (en) 2010-02-03 2014-06-30 Takeda Pharmaceutical Company Limited KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
US20160263189A1 (en) 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays

Also Published As

Publication number Publication date
BR9406616A (pt) 1996-02-06
EP0694078A1 (fr) 1996-01-31
WO1994023068A1 (fr) 1994-10-13
EP0694078A4 (fr) 1997-06-25
JPH08512197A (ja) 1996-12-24
AU6556194A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
Tzukerman et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.
Pham et al. Ligand-dependent and-independent function of the transactivation regions of the human estrogen receptor in yeast.
Webster et al. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function
Goldberg et al. Activation of protein kinase C or cAMP‐dependent protein kinase increases phosphorylation of the c‐erbA‐encoded thyroid hormone receptor and of the v‐erbA‐encoded protein.
US5445941A (en) Method for screening anti-osteoporosis agents
CA2160135A1 (fr) Methode pour depister les agonistes de recepteurs
US5723291A (en) Methods for screening compounds for estrogenic activity
EP0629697A2 (fr) Matériael et méthodes de screening d'agents anti-ostéoporotiques
WO1996041013A1 (fr) Procedes de depistage d'agonistes et d'antagonistes de recepteurs
US20080014585A1 (en) Synergistic activation of regulatory elements by rel proteins and a steroid receptor
US6156723A (en) Compositions comprising inhibitors of estrogen response
EP0898708B1 (fr) Interaction de la cycline d1 avec le recepteur d'oestrogene et son utilisation dans des dosages
JP2003526346A5 (fr)
Reese Jr Molecular actions of estrogen agonists and antagonists and their interaction with the human estrogen receptor
WO2000026232A1 (fr) Represseur de l'activite du recepteur des oestrogenes
Zhong Role of the conserved tyrosine 537 on hormone binding and stability in the human estrogen receptor
Schmid et al. Steroid Response Elements: Composite Structure and Definition of a Minimal Element
Handel Novel mechanisms of action of progesterone receptor and progesterone antagonists
Zhuang Mechanistic analysis of estrogen receptor action using dominant negative mutants
Borgo Luigi Cicatiello,† Raffaele Addeo,† Annarita Sasso, Lucia Altucci, Valeria Belsito Petrizzi, Raphaelle Borgo, Massimo Cancemi, Simona Caporali, Silvana Caristi, Claudio Scafoglio, Diana Teti, 2 Francesco Bresciani, Bruno Perillo, 3 and Alessandro Weisz1
Rapiejko Characterization of point mutations of the ligand-binding domain of the human estrogen receptor
Katzenellenbogen et al. Cyclic AMP Modulation of Estrogen-Induced Effects: A Novel Mechanism for Hormonal Resistance in Breast Cancer
Jackson Isolation and characterization of a novel coactivator and corepressor of antagonist-mediated steroid receptor transcription

Legal Events

Date Code Title Description
FZDE Dead